Jean Yu, MD
Obstetrics & Gynecology · San Francisco, CANPI 1548407950
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 126 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by AbbVie at 24.2% of the total. Reporting peaked in 2021 at $582 and has fallen 96.2% since, to $22 in 2025.
Across 126 payments — averaging $20.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$638
- Mayne Pharma Commercial LLC$200
- Avion Pharmaceuticals$183
- Amgen$182
- Coopersurgical, Inc.$171
- Hologic Sales And Service, LLC$156
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,638100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 29 | $638 |
| Mayne Pharma Commercial LLC | 10 | $200 |
| Avion Pharmaceuticals | 15 | $183 |
| Amgen | 7 | $182 |
| Coopersurgical, Inc. | 6 | $171 |
| Hologic Sales And Service, LLC | 7 | $156 |
| Bayer | 8 | $152 |
| Therapeuticsmd, Inc. | 6 | $120 |
| Organon | 4 | $96 |
| Astellas Pharma US Inc | 2 | $93 |
| Merck | 5 | $86 |
| Roche Diagnostics Corporation | 4 | $85 |
| W. L. Gore & Associates, Inc. | 1 | $85 |
| Ascend Therapeutics US, LLC | 4 | $49 |
| Pfizer | 2 | $36 |
| Shield Therapeutics Inc | 2 | $31 |
| Lupin Inc. | 1 | $27 |
| Sanofi Pasteur Inc. | 1 | $24 |
| SK Life Science, Inc. | 1 | $23 |
| Mylan Pharmaceuticals Inc. | 1 | $22 |
| Novocure Inc. | 1 | $22 |
| Olympus America Inc. | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Agile Therapeutics, Inc. | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Davol Inc. | 1 | $18 |
| Aspira Women's Health Inc | 1 | $17 |
| Pacira Pharmaceuticals Incorporated | 1 | $17 |
| Dilon Technologies, Inc. | 1 | $13 |
| Vertical Pharmaceuticals, LLC | 1 | $11 |
How this compares
$2,638 in reported general payments places this provider in the 80th percentile of 3,784 obstetrics & gynecology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other obstetrics & gynecology in San Francisco
- Maida TaylorSan Francisco$279K
- Mona OradySan Francisco$224K
- Mitchell RosenSan Francisco$67K
- Leslie KardosSan Francisco$31K
- Steve YuNorthridge$964K
- Samir HageRedlands$640K
- Malcolm MunroLos Angeles$609K
- Michael KrychmanCosta Mesa$547K
- Anita NelsonTorrance$530K
- Jan SegnitzSan Jose$511K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.